1211-STING Unlocks CD4+ T Cell Immunity in Pancreatic Cancer
Recent research indicates that pancreatic ductal adenocarcinoma, a typically treatment-resistant cancer, can be successfully managed by combining checkpoint blockade with STING-mediated immune stimulation. This study demonstrates that a triple therapy involving anti-PD-1, anti-CTLA-4, and a STING agonist triggers an unconventional immune response independent of the usual cytotoxic CD8+ T cells. Instead, the treatment activates cDC2 dendritic cells, which migrate to lymph nodes to prime CD4+ T cells for tumor destruction. These specialized helper cells then release the cytokine IFN-γ to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.